Distribution of individuals and ORs of cancer according to EPHX1 genotypes and predicted mEH activity
| Genotype . | Oral/pharyngeal cancer patients (n = 121) . | . | Laryngeal cancer patients (n = 129) . | . | Control individuals (n = 172) . | ||
|---|---|---|---|---|---|---|---|
| . | n (%) . | ORa (95% CI) . | n (%) . | ORa (95% CI) . | n (%) . | ||
| Exon 3 genotypes | |||||||
| wt3/wt3b | 66 (54.5) | 1 (Reference) | 72 (55.8) | 1 (Reference) | 64 (37.2) | ||
| wt3/slow | 32 (26.5) | 0.4 (0.2–0.7) | 40 (31.0) | 0.4 (0.2–0.7) | 77 (44.8) | ||
| slow/slow | 23 (19.0) | 0.8 (0.4–1.8) | 17 (13.2) | 0.5 (0.2–1.1) | 31 (18.0) | ||
| P for trend | 0.17 | 0.006 | |||||
| Exon 4 genotypes | |||||||
| wt4/wt4 | 80 (66.1) | 1 (Reference) | 84 (65.1) | 1 (Reference) | 121 (70.3) | ||
| wt4/rapid | 38 (31.4) | 1.1 (0.6–2.0)c | 41 (31.8) | 1.0 (0.6–1.8)c | 49 (28.5) | ||
| rapid/rapid | 3 (2.5) | 4 (3.1) | 2 (1.2) | ||||
| Predicted mEH activity | |||||||
| Lowd | 42 (34.7) | 1 (Reference) | 43 (33.3) | 1 (Reference) | 85 (49.4) | ||
| Intermediatee | 55 (45.5) | 1.8 (1.0–3.3) | 59 (45.7) | 1.7 (1.0–3.1) | 65 (37.8) | ||
| Highf | 24 (19.8) | 2.1 (1.0–4.5) | 27 (20.9) | 2.4 (1.1–5.1) | 22 (12.8) | ||
| P for trend | 0.03 | 0.02 | |||||
| Genotype . | Oral/pharyngeal cancer patients (n = 121) . | . | Laryngeal cancer patients (n = 129) . | . | Control individuals (n = 172) . | ||
|---|---|---|---|---|---|---|---|
| . | n (%) . | ORa (95% CI) . | n (%) . | ORa (95% CI) . | n (%) . | ||
| Exon 3 genotypes | |||||||
| wt3/wt3b | 66 (54.5) | 1 (Reference) | 72 (55.8) | 1 (Reference) | 64 (37.2) | ||
| wt3/slow | 32 (26.5) | 0.4 (0.2–0.7) | 40 (31.0) | 0.4 (0.2–0.7) | 77 (44.8) | ||
| slow/slow | 23 (19.0) | 0.8 (0.4–1.8) | 17 (13.2) | 0.5 (0.2–1.1) | 31 (18.0) | ||
| P for trend | 0.17 | 0.006 | |||||
| Exon 4 genotypes | |||||||
| wt4/wt4 | 80 (66.1) | 1 (Reference) | 84 (65.1) | 1 (Reference) | 121 (70.3) | ||
| wt4/rapid | 38 (31.4) | 1.1 (0.6–2.0)c | 41 (31.8) | 1.0 (0.6–1.8)c | 49 (28.5) | ||
| rapid/rapid | 3 (2.5) | 4 (3.1) | 2 (1.2) | ||||
| Predicted mEH activity | |||||||
| Lowd | 42 (34.7) | 1 (Reference) | 43 (33.3) | 1 (Reference) | 85 (49.4) | ||
| Intermediatee | 55 (45.5) | 1.8 (1.0–3.3) | 59 (45.7) | 1.7 (1.0–3.1) | 65 (37.8) | ||
| Highf | 24 (19.8) | 2.1 (1.0–4.5) | 27 (20.9) | 2.4 (1.1–5.1) | 22 (12.8) | ||
| P for trend | 0.03 | 0.02 | |||||
ORs adjusted for sex-, age-, smoking-, and alcohol-related variables. Data on smoking and/or alcohol drinking were missing for six oral/pharynx cancer cases, six larynx cancer cases, and eight control individuals.
wt, wild type.
Due to small number of rapid/rapidgenotype, ORs were calculated for combined wt4/rapid and rapid/rapidgenotypes.
slow/slow and wt4/wt4 genotypes, slow/slow and wt4/rapidgenotypes, wt3/slow and wt4/wt4 genotypes.
wt3/wt3 and wt4/wt4 genotypes, wt3/slow and wt4/rapid genotypes.
wt3/wt3 and wt4/rapid genotypes, wt3/wt3 and rapid/rapidgenotypes, wt3/slow and rapid/rapidgenotypes.